Lexaria Bioscience Corp.

01/15/2025 | Press release | Distributed by Public on 01/15/2025 11:02

Proxy Results Form 8 K

Item 5.07 Submission of Matters to a Vote of Security Holders

On January 14, 2025 at 1:00 p.m. (Pacific Time), the Company held its annual and special shareholder meeting (the "Meeting"). There were 9,761,279 shares of the Company represented in person or by proxy at the Meeting, constituting 55.93% of the Company's issued share capital as at November 18, 2024, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:

Matter Being Voted On

For

Against/

Withheld

Abstain

Broker Non-Vote

Percent

Approved By1

To Elect Chris Bunka as a director

5,168,004 608,879 - 3,984,396 89 %

To Elect John Docherty as a director

5,635,178 141,705 - 3,984,396 98 %

To Elect Nicholas Baxter as a director

3,600,923 2,177,149 - 3,983,207 62 %

To Elect Ted McKechnie as a director

3,100,882 2,677,190 - 3,983,207 54 %

To Elect Albert Reese Jr. as a director

5,208,406 569,666 - 3,983,207 90 %

To Elect Richard Christopher as a director

5,682,948 95,124 - 3,983,207 98 %

To Elect Bal Bhullar as a director

5,679,731 98,341 - 3,983,207 98 %

To Appoint Malone Bailey LLP as Auditors

9,544,943 192,543 27,793 - 98 %

To Approve Executive Compensation

5,580,530 150,814 46,727 3,983,208 97 %

To Approve Executive Compensation Annually2

1,828,002 - 119,054 3,983,207 32 %

To Approve Executive Compensation every two years

45,224 - 119,054 3,983,207 1 %

To Approve Executive Compensation every three years

3,785,792 - 119,054 3,983,207 66 %

To Approve the Warrant Exercise Proposal

4,024,010 1,663,342 90,719 3,983,208 70 %

To Ratify the lawful actions of the directors for the past year

5,268,595 412,730 96,747 3,983,207 91 %

1 Percentage is calculated based on abstained votes and broker non-votes not being counted as a vote against the resolution.

2 The timing for the approval of the executive compensation was issued as one proposal, accordingly the number of votes abstaining and representing broker non-votes for each frequency option are not cumulative.

All of the proposals are described in detail in the Company's proxy statement filed with the Securities and Exchange Commission on November 27, 2024.

2